Ovarian cancer in the world: epidemiology and risk factors

References

• Momenimovahed Z, Ghoncheh M, Pakzad R, Hasanpour H, Salehiniya H. Incidence and mortality of uterine cancer and relationship with human development index in the world. Cukurova Med J. 2017;42(2):233–240. doi:10.17826/cutf.322865
   Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.30207593
   PubMed Web of Science ®Google Scholar
• Coburn S, Bray F, Sherman M, Trabert B. International patterns and trends in ovarian cancer incidence, overall and by histologic subtype. Int J Cancer. 2017;140(11):2451–2460. doi:10.1002/ijc.3067628257597
   PubMed Web of Science ®Google Scholar
• Yoneda A, Lendorf ME, Couchman JR, Multhaupt HA. Breast and ovarian cancers: a survey and possible roles for the cell surface heparan sulfate proteoglycans. J Histochem Cytochem. 2012;60(1):9–21. doi:10.1369/002215541142846922205677
   PubMed Web of Science ®Google Scholar
• Jacobs IJ, Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics. 2004;3(4):355–366. doi:10.1074/mcp.R400006-MCP20014764655
   PubMed Web of Science ®Google Scholar
• Badgwell D, Bast JRC. Early detection of ovarian cancer. Dis Markers. 2007;23(5–6):397–410.18057523
   PubMed Web of Science ®Google Scholar
• Lowe KA, Chia VM, Taylor A, et al. An international assessment of ovarian cancer incidence and mortality. Gynecol Oncol. 2013;130(1):107–114. doi:10.1016/j.ygyno.2013.03.02623558050
   PubMed Web of Science ®Google Scholar
• Hunn J, Rodriguez GC. Ovarian cancer: etiology, risk factors, and epidemiology. Clin Obstet Gynecol. 2012;55(1):3–23.22343225
   PubMed Web of Science ®Google Scholar
• Torre LA, Trabert B, DeSantis CE, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68(4):284–296.29809280
   PubMed Web of Science ®Google Scholar
• Chornokur G, Amankwah EK, Schildkraut JM, Phelan CM. Global ovarian cancer health disparities. Gynecol Oncol. 2013;129(1):258–264. doi:10.1016/j.ygyno.2012.12.01623266352
   PubMed Web of Science ®Google Scholar
• Bell DA. Origins and molecular pathology of ovarian cancer. Modern Pathol. 2005;18(S2):S19. doi:10.1038/modpathol.3800306
   Web of Science ®Google Scholar
• Andrews L, Mutch DG. Hereditary ovarian cancer and risk reduction. Best Pract Res Clin Obstet Gynaecol. 2017;41:31–48. doi:10.1016/j.bpobgyn.2016.10.01728254144
   PubMed Web of Science ®Google Scholar
• Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017;14(1):9. doi:10.20892/j.issn.2095-3941.2016.008428443200
   PubMed Web of Science ®Google Scholar
• Prat J. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Archiv. 2012;460(3):237–249. doi:10.1007/s00428-012-1203-522322322
   PubMed Web of Science ®Google Scholar
• Lukanova A, Kaaks R. Endogenous hormones and ovarian cancer: epidemiology and current hypotheses. Cancer Epidemiol Prev Biomarkers. 2005;14(1):98–107.
   PubMed Web of Science ®Google Scholar
• McCluggage WG. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology. 2011;43(5):420–432. doi:10.1097/PAT.0b013e328348a6e721716157
   PubMed Web of Science ®Google Scholar
• Vang R, Shih I-M, Kurman RJ. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol. 2009;16(5):267. doi:10.1097/PAP.0b013e3181b4fffa19700937
   PubMed Web of Science ®Google Scholar
• Kurman R, Carcangiu M, Herrington C, Young R. WHO Classification of Tumours of Female ReSroductive Organs. Lyon: IARC; 2014.
   Google Scholar
• Kurman RJ, Shih I-M. The origin and pathogenesis of epithelial ovarian cancer-a proposed unifying theory. Am J Surg Pathol. 2010;34(3):433. doi:10.1097/PAS.0b013e3181cf3d7920154587
   PubMed Web of Science ®Google Scholar
• Isherwood A, Bamford J, Dupuy AV. Ovarian cancer in select EU countries: incidence, treatable populations and sales by key drug class. Rev Epidemiol Sante Publique. 2018;66:S286. doi:10.1016/j.respe.2018.05.131
   Google Scholar
• Sopik V, Iqbal J, Rosen B, Narod SA. Why have ovarian cancer mortality rates declined? Part I. Incidence. Gynecol Oncol. 2015;138(3):741–749. doi:10.1016/j.ygyno.2015.06.01726080287
   PubMed Web of Science ®Google Scholar
• Rahmani K, Moradi-Lakeh M, Mansori K, Bidokhti F, Asadi-Lari M. global inequalities in incidence and mortality of ovarian cancer and associated factors: an ecological study. Alzheimers Park Res Ther. 2018;1:1.
   Google Scholar
• Razi S, Ghoncheh M, Mohammadian-Hafshejani A, Aziznejhad H, Mohammadian M, Salehiniya H. The incidence and mortality of ovarian cancer and their relationship with the human development index in Asia. Cancermedicalscience. 2016;10:628.
   Google Scholar
• Malvezzi M, Carioli G, Rodriguez T, Negri E, La Vecchia C. Global trends and predictions in ovarian cancer mortality. Ann Oncol. 2016;27(11):2017–2025. doi:10.1093/annonc/mdw30627597548
   PubMed Web of Science ®Google Scholar
• Ørskov M, Iachina M, Guldberg R, Mogensen O, Nørgård BM. Predictors of mortality within 1 year after primary ovarian cancer surgery: a nationwide cohort study. BMJ Open. 2016;6(4):e010123.
   PubMed Web of Science ®Google Scholar
• Tetsche MS, Dethlefsen C, Pedersen L, Sorensen HT, Norgaard M. The impact of comorbidity and stage on ovarian cancer mortality: a nationwide Danish cohort study. BMC Cancer. 2008;8(1):31. doi:10.1186/1471-2407-8-17218230177
   PubMed Web of Science ®Google Scholar
• Chan J, Urban R, Cheung M, et al. Ovarian cancer in younger vs older women: a population-based analysis. Br J Cancer. 2006;95(10):1314. doi:10.1038/sj.bjc.660345717088903
   PubMed Web of Science ®Google Scholar
• Mohammadian M, Ghafari M, Khosravi B, et al. Variations in the incidence and mortality of ovarian cancer and their relationship with the human development index in European Countries in 2012. Biomed Res Ther. 2017;4(08):1541–1557. doi:10.15419/bmrat.v4i08.228
   Google Scholar
• Arora N, Talhouk A, McAlpine JN, Law MR, Hanley GE. Long-term mortality among women with epithelial ovarian cancer: a population-based study in British Columbia, Canada. BMC Cancer. 2018;18(1):1039. doi:10.1186/s12885-018-4242-830359249
   PubMed Web of Science ®Google Scholar
• Zheng G, Yu H, Kanerva A, Försti A, Sundquist K, Hemminki K. Familial risks of ovarian cancer by age at diagnosis, proband type and histology. PLoS One. 2018;13(10):e0205000. doi:10.1371/journal.pone.020500030281663
   PubMed Web of Science ®Google Scholar
• Chan JK, Loizzi V, Lin YG, et al. IV invasive epithelial ovarian carcinoma in younger versus older women: what prognostic factors are important? Obstet Gynecol. 2003;102(1):156–161.12850623
   PubMed Web of Science ®Google Scholar
• Chan JK, Loizzi V, Magistris A, et al. Differences in prognostic molecular markers between women over and under 45 years of age with advanced ovarian cancer. Clin Cancer Res. 2004;10(24):8538–8543. doi:10.1158/1078-0432.CCR-04-062615623636
   PubMed Web of Science ®Google Scholar
• Massi D, Susini T, Savino L, Boddi V, Amunni G, Colafranceschi M. Epithelial ovarian tumors in the reproductive age group: age is not an independent prognostic factor. Cancer. 1996;77(6):1131–1136.8635134
   PubMed Web of Science ®Google Scholar
• Poole EM, Merritt MA, Jordan SJ, et al. Hormonal and reproductive risk factors for epithelial ovarian cancer by tumor aggressiveness. Cancer Epidemiol Prev Biomarkers. 2013. doi:10.1158/1055-9965.EPI-12-1183-T
   Web of Science ®Google Scholar
• Ries LA. Ovarian cancer. Survival and treatment differences by age. Cancer. 1993;71(2 Suppl):524–529.8420672
   PubMed Web of Science ®Google Scholar
• Tung K, Goodman M, Wu A, et al. Reproductive factors and epithelial ovarian cancer risk by histologic type: a multiethnic case-control study. Am J Epidemiol. 2003;158(7):629–638.14507598
   PubMed Web of Science ®Google Scholar
• Mori M, Harabuchi I, Miyake H, Casagrande JT, Henderson BE, Ross RK. Reproductive, genetic, and dietary risk factors for ovarian cancer. Am J Epidemiol. 1988;128(4):771–777.3421242
   PubMed Web of Science ®Google Scholar
• Kim SJ, Rosen B, Fan I, et al. Epidemiologic factors that predict long-term survival following a diagnosis of epithelial ovarian cancer. Br J Cancer. 2017;116(7):964. doi:10.1038/bjc.2017.3528208158
   PubMed Web of Science ®Google Scholar
• Salazar-Martinez E, Lazcano-Ponce EC, Gonzalez Lira-Lira G, Escudero-De Los Rios P, Salmeron-Castro J, Hernandez-Avila M. Reproductive factors of ovarian and endometrial cancer risk in a high fertility population in Mexico. Cancer Res. 1999;59(15):3658–3662.10446978
   PubMed Web of Science ®Google Scholar
• Fathalla MF. Incessant ovulation–a factor in ovarian neoplasia? Lancet. 1971;2(7716):163. doi:10.1016/S0140-6736(71)92335-X4104488
   PubMed Web of Science ®Google Scholar
• Moorman P, Schildkraut J, Calingaert B, Halabi S, Vine M, Berchuck A. Ovulation and ovarian cancer: a comparison of two methods for calculating lifetime ovulatory cycles (United States). Cancer Causes Control. 2002;13(9):807–811. doi:10.1023/A:102067810097712462545
   PubMed Web of Science ®Google Scholar
• Fujita M, Tase T, Kakugawa Y, et al. Smoking, earlier menarche and low parity as independent risk factors for gynecologic cancers in Japanese: a case-control study. Tohoku J Exp Med. 2008;216(4):297–307.19060444
   PubMed Web of Science ®Google Scholar
• Jordan SJ, Webb PM, Green AC. Height, age at menarche, and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2005;14(8):2045–2048.16103459
   PubMed Web of Science ®Google Scholar
• Titus-Ernstoff L, Perez K, Cramer D, Harlow B, Baron J, Greenberg E. Menstrual and reproductive factors in relation to ovarian cancer risk. Br J Cancer. 2001;84(5):714. doi:10.1054/bjoc.2000.159611237375
   PubMed Web of Science ®Google Scholar
• Kvale G, Heuch I, Nilssen S, Beral V. Reproductive factors and risk of ovarian cancer: a prospective study. Int J Cancer. 1988;42(2):246–251.3403067
   PubMed Web of Science ®Google Scholar
• Kurian AW, Balise RR, McGuire V, Whittemore AS. Histologic types of epithelial ovarian cancer: have they different risk factors? Gynecol Oncol. 2005;96(2):520–530. doi:10.1016/j.ygyno.2004.10.03715661246
   PubMed Web of Science ®Google Scholar
• Franceschi S, La Vecchia C, Booth M, et al. Pooled analysis of 3 European case‐control studies of ovarian cancer: II. Age at menarche and at menopause. Int J Cancer. 1991;49(1):57–60.1874570
   PubMed Web of Science ®Google Scholar
• Weiderpass E, Sandin S, Inoue M, et al. Risk factors for epithelial ovarian cancer in Japan - results from the Japan Public Health Center-based Prospective Study cohort. Int J Oncol. 2012;40(1):21–30. doi:10.3892/ijo.2011.119421904774
   PubMed Web of Science ®Google Scholar
• Hankinson SE, Colditz GA, Hunter DJ, et al. A prospective study of reproductive factors and risk of epithelial ovarian cancer. Cancer. 1995;76(2):284–290.8625104
   PubMed Web of Science ®Google Scholar
• Riman T, Dickman PW, Nilsson S, et al. Risk factors for epithelial borderline ovarian tumors: results of a Swedish case-control study. Gynecol Oncol. 2001;83(3):575–585. doi:10.1006/gyno.2001.645111733975
   PubMed Web of Science ®Google Scholar
• Soegaard M, Jensen A, Hogdall E, et al. Different risk factor profiles for mucinous and nonmucinous ovarian cancer: results from the Danish MALOVA study. Cancer Epidemiol Biomarkers Prev. 2007;16(6):1160–1166. doi:10.1158/1055-9965.EPI-07-008917548679
   PubMed Web of Science ®Google Scholar
• Huusom LD, Frederiksen K, Hogdall EV, et al. Association of reproductive factors, oral contraceptive use and selected lifestyle factors with the risk of ovarian borderline tumors: a Danish case-control study. Cancer Causes Control. 2006;17(6):821–829. doi:10.1007/s10552-006-0022-x16783610
   PubMed Web of Science ®Google Scholar
• Risch HA, Marrett LD, Jain M, Howe GR. Differences in risk factors for epithelial ovarian cancer by histologic type: results of a case-control study. Am J Epidemiol. 1996;144(4):363–372.8712193
   PubMed Web of Science ®Google Scholar
• Adami H-O, Lambe M, Persson I, et al. Parity, age at first childbirth, and risk of ovarian cancer. Lancet. 1994;344(8932):1250–1254. doi:10.1016/S0140-6736(94)90749-87967985
   PubMed Web of Science ®Google Scholar
• Jordan SJ, Green AC, Nagle CM, et al. Beyond parity: association of ovarian cancer with length of gestation and offspring characteristics. Am J Epidemiol. 2009;170(5):607–614. doi:10.1093/aje/kwp18519638480
   PubMed Web of Science ®Google Scholar
• Sköld C, Bjørge T, Ekbom A, et al. Preterm delivery is associated with an increased risk of epithelial ovarian cancer among parous women. Int J Cancer. 2018;143:1858–1867. doi:10.1002/ijc.3158129737528
   PubMed Web of Science ®Google Scholar
• Mucci LA, Dickman PW, Lambe M, et al. Gestational age and fetal growth in relation to maternal ovarian cancer risk in a Swedish cohort. Cancer Epidemiol Prev Biomarkers. 2007;16(9):1828–1832. doi:10.1158/1055-9965.EPI-06-0962
   Web of Science ®Google Scholar
• Calderon-Margalit R, Friedlander Y, Yanetz R, et al. Preeclampsia and subsequent risk of cancer: update from the Jerusalem Perinatal Study. Am J Obstet Gynecol. 2009;200(1):63.e1-. e5. doi:10.1016/j.ajog.2008.06.057
   Web of Science ®Google Scholar
• Moorman PG, Calingaert B, Palmieri RT, et al. Hormonal risk factors for ovarian cancer in premenopausal and postmenopausal women. Am J Epidemiol. 2008;167(9):1059–1069. doi:10.1093/aje/kwn00618303003
   PubMed Web of Science ®Google Scholar
• Ness RB, Grisso JA, Cottreau C, et al. Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer. Epidemiology. 2000;11(2):111–117.11021606
   PubMed Web of Science ®Google Scholar
• Jia D, Nagaoka Y, Katsumata M, Orsulic S. Inflammation is a key contributor to ovarian cancer cell seeding. Sci Rep. 2018;8(1):12394. doi:10.1038/s41598-018-30261-830120290
   PubMed Web of Science ®Google Scholar
• Ness RB, Goodman MT, Shen C, Brunham RC. Serologic evidence of past infection with Chlamydia trachomatis, in relation to ovarian cancer. J Infect Dis. 2003;187(7):1147–1152. doi:10.1086/36838012660930
   PubMed Web of Science ®Google Scholar
• Wong A, Maclean AB, Furrows SJ, Ridgway GL, Hardiman PJ, Perrett CW. Could epithelial ovarian cancer be associated with chlamydial infection? Eur J Gynaecol Oncol. 2007;28(2):117–120.17479672
   PubMed Web of Science ®Google Scholar
• Merritt MA, Green AC, Nagle CM, Webb PM. Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer. Int J Cancer. 2008;122(1):170–176. doi:10.1002/ijc.2301717721999
   PubMed Web of Science ®Google Scholar
• Lin H-W, Tu -Y-Y, Lin SY, et al. Risk of ovarian cancer in women with pelvic inflammatory disease: a population-based study. Lancet Oncol. 2011;12(9):900–904. doi:10.1016/S1470-2045(11)70165-621835693
   PubMed Web of Science ®Google Scholar
• Rasmussen CB, Jensen A, Albieri V, Andersen KK, Kjaer SK. Is pelvic inflammatory disease a risk factor for Ovarian cancer? Cancer Epidemiol Biomarkers Prev. 2017;26(1):104–109. doi:10.1158/1055-9965.EPI-16-045927672055
   PubMed Web of Science ®Google Scholar
• Risch HA, Howe GR. Pelvic inflammatory disease and the risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 1995;4(5):447–451.7549798
   PubMed Web of Science ®Google Scholar
• Chiang AJ, Chang C, Huang C-H, Huang W-C, Kan Y-Y CJ. Risk factors in progression from endometriosis to ovarian cancer: a cohort study based on medical insurance data. J Gynecol Oncol. 2018;29:3. doi:10.3802/jgo.2018.29.e28
   Web of Science ®Google Scholar
• Sampson JA. Endometrial carcinoma of the ovary, arising in endometrial tissue in that organ. Arch Surg. 1925;10(1):1–72. doi:10.1001/archsurg.1925.01120100007001
   Google Scholar
• Pavone ME, Lyttle BM. Endometriosis and ovarian cancer: links, risks, and challenges faced. Int J Womens Health. 2015;7:663. doi:10.2147/IJWH.S6682426170722
   PubMed Web of Science ®Google Scholar
• Mogensen JB, Kjær SK, Mellemkjær L, Jensen A. Endometriosis and risks for ovarian, endometrial and breast cancers: a nationwide cohort study. Gynecol Oncol. 2016;143(1):87–92. doi:10.1016/j.ygyno.2016.07.09527430396
   PubMed Web of Science ®Google Scholar
• Melin A, Sparen P, Persson I, Bergqvist A. Endometriosis and the risk of cancer with special emphasis on ovarian cancer. Hum Reprod. 2006;21(5):1237–1242. doi:10.1093/humrep/dei46216431901
   PubMed Web of Science ®Google Scholar
• Stewart LM, Holman CAJ, Aboagye-Sarfo P, Finn JC, Preen DB, Hart R. In vitro fertilization, endometriosis, nulliparity and ovarian cancer risk. Gynecol Oncol. 2013;128(2):260–264. doi:10.1016/j.ygyno.2012.10.02323116937
   PubMed Web of Science ®Google Scholar
• Erzen M, Kovacic J. Relationship between endometriosis and ovarian cancer. Eur J Gynaecol Oncol. 1998;19(6):553–555.10215439
   PubMed Web of Science ®Google Scholar
• Wang K-C, Chang W-H, Lee W-L, et al. An increased risk of epithelial ovarian cancer in Taiwanese women with a new surgico-pathological diagnosis of endometriosis. BMC Cancer. 2014;14(1):831.25403543
   PubMed Web of Science ®Google Scholar
• Zanetta GM, Webb MJ, Li H, Keeney GL. Hyperestrogenism: a relevant risk factor for the development of cancer from endometriosis. Gynecol Oncol. 2000;79(1):18–22.11006024
   PubMed Web of Science ®Google Scholar
• Cottreau CM, Ness RB, Modugno F, Allen GO, Goodman MT. Endometriosis and its treatment with danazol or lupron in relation to ovarian cancer. Clin Cancer Res. 2003;9(14):5142–5144.14613992
   PubMed Web of Science ®Google Scholar
• Rossing MA, Cushing-Haugen KL, Wicklund KG, Doherty JA, Weiss NS. Risk of epithelial ovarian cancer in relation to benign ovarian conditions and ovarian surgery. Cancer Causes Control. 2008;19(10):1357.18704718
   PubMed Web of Science ®Google Scholar
• Caserta R, Nesti E, Caserta L, Guerriero V, Di Francesco D, Panariello S. [Small ovarian cysts in postmenopause: assessment of their malignant potential with vaginal ultrasonography and tumor marker Ca125 titration]. Minerva Ginecol. 2001;53(1 Suppl 1):120–124.11526706
   PubMedGoogle Scholar
• Hartge P, Hayes R, Reding D, et al. Complex ovarian cysts in postmenopausal women are not associated with ovarian cancer risk factors: preliminary data from the prostate, lung, colon, and ovarian cancer screening trial. Am J Obstet Gynecol. 2000;183(5):1232–1237.11084571
   PubMed Web of Science ®Google Scholar
• Crayford TJ, Campbell S, Bourne TH, Rawson HJ, Collins WP. Benign ovarian cysts and ovarian cancer: a cohort study with implications for screening. Lancet. 2000;355(9209):1060–1063.10744092
   PubMed Web of Science ®Google Scholar
• Sieh W, Salvador S, McGuire V, et al. Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies. Int J Epidemiol. 2013;42(2):579–589.23569193
   PubMed Web of Science ®Google Scholar
• Ness RB, Dodge RC, Edwards RP, Baker JA, Moysich KB. Contraception methods, beyond oral contraceptives and tubal ligation, and risk of ovarian cancer. Ann Epidemiol. 2011;21(3):188–196.21109450
   PubMed Web of Science ®Google Scholar
• Ness RB, Grisso JA, Vergona R, Klapper J, Morgan M, Wheeler JE. Oral contraceptives, other methods of contraception, and risk reduction for ovarian cancer. Epidemiology. 2001;12(3):307–312.11337604
   PubMed Web of Science ®Google Scholar
• Madsen C, Baandrup L, Dehlendorff C, Kjaer SK. Tubal ligation and salpingectomy and the risk of epithelial ovarian cancer and borderline ovarian tumors: a nationwide case-control study. Acta Obstet Gynecol Scand. 2015;94(1):86–94.25256594
   PubMed Web of Science ®Google Scholar
• Gaitskell K, Green J, Pirie K, Reeves G, Beral V. Collaborators obotMWS. Tubal ligation and ovarian cancer risk in a large cohort: substantial variation by histological type. Int J Cancer. 2016;138(5):1076–1084.26378908
   PubMed Web of Science ®Google Scholar
• Cibula D, Widschwendter M, Zikan M, Dusek L. Underlying mechanisms of ovarian cancer risk reduction after tubal ligation. Acta Obstet Gynecol Scand. 2011;90(6):559–563.21355863
   PubMed Web of Science ®Google Scholar
• Tsilidis K, Allen N, Key T, et al. Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective investigation into cancer and nutrition. Br J Cancer. 2011;105(9):1436.21915124
   PubMed Web of Science ®Google Scholar
• Royar J, Becher H, Chang-Claude J. Low-dose oral contraceptives: protective effect on ovarian cancer risk. Int J Cancer. 2001;95(6):370–374.11668519
   PubMed Web of Science ®Google Scholar
• La Vecchia C, Franceschi S. Oral contraceptives and ovarian cancer. Eur J Cancer Prev. 1999;8(4):297–304.10493304
   PubMed Web of Science ®Google Scholar
• Rossing MA, Cushing-Haugen KL, Wicklund KG, Doherty JA, Weiss NS. Menopausal hormone therapy and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2007;16(12):2548–2556.18086757
   PubMed Web of Science ®Google Scholar
• Hempling RE, Wong C, Piver MS, Natarajan N, Mettlin CJ. Hormone replacement therapy as a risk factor for epithelial ovarian cancer: results of a case-control study. Obstet Gynecol. 1997;89(6):1012–1016.9170483
   PubMed Web of Science ®Google Scholar
• Glud E, Kjaer S, Thomsen B, et al. Hormone therapy and the impact of estrogen intake on the risk of ovarian cancer. Arch Intern Med. 2004;164(20):2253–2259.15534163
   PubMedGoogle Scholar
• Lacey JV Jr, Mink PJ, Lubin JH, et al. Menopausal hormone replacement therapy and risk of ovarian cancer. Jama. 2002;288(3):334–341.12117398
   PubMed Web of Science ®Google Scholar
• Wernli KJ, Newcomb PA, Hampton JM, Trentham-Dietz A, Egan KM. Hormone therapy and ovarian cancer: incidence and survival. Cancer Causes Control. 2008;19(6):605–613.18264784
   PubMed Web of Science ®Google Scholar
• Mørch LS, Løkkegaard E, Andreasen AH, Krüger-Kjær S, Lidegaard Ø. Hormone therapy and ovarian cancer. Jama. 2009;302(3):298–305.19602689
   PubMed Web of Science ®Google Scholar
• Liat L-G, Jaron R, Liraz O, Shlomo M, Bruno L. Are infertility treatments a potential risk factor for cancer development? Perspective of 30 years of follow-up. Gynecol Endocrinol. 2012;28(10):809–814.22475084
   PubMed Web of Science ®Google Scholar
• Reigstad MM, Storeng R, Myklebust TÅ, et al. Cancer risk in women treated with fertility drugs according to parity status—A registry-based cohort study. Cancer Epidemiol Biomarkers Prev. 2017;26(6):953–962.28108444
   PubMed Web of Science ®Google Scholar
• Brinton LA, Lamb EJ, Moghissi KS, et al. Ovarian cancer risk after the use of ovulation-stimulating drugs. Obstet Gynecol. 2004;103(6):1194–1203. doi:10.1097/01.AOG.0000128139.92313.7415172852
   PubMed Web of Science ®Google Scholar
• Shushan A, Paltiel O, Iscovich J, Elchalal U, Peretz T, Schenker JG. Human menopausal gonadotropin and the risk of epithelial ovarian cancer. Fertil Steril. 1996;65(1):13–18.8557128
   PubMed Web of Science ®Google Scholar
• Dos Santos Silva I, Wark P, McCormack V, et al. Ovulation-stimulation drugs and cancer risks: a long-term follow-up of a British cohort. Br J Cancer. 2009;100(11):1824. doi:10.1038/sj.bjc.660508619436296
   PubMed Web of Science ®Google Scholar
• Calderon-Margalit R, Friedlander Y, Yanetz R, et al. Cancer risk after exposure to treatments for ovulation induction. Am J Epidemiol. 2008;169(3):365–375. doi:10.1093/aje/kwn31819037008
   PubMed Web of Science ®Google Scholar
• Potashnik G, Lerner-Geva L, Genkin L, Chetrit A, Lunenfeld E, Porath A. Fertility drugs and the risk of breast and ovarian cancers: results of a long-term follow-up study. Fertil Steril. 1999;71(5):853–859.10231045
   PubMed Web of Science ®Google Scholar
• Venn A, Watson L, Lumley J, Gilles G, King C, Healy D. Breast and ovarian cancer incidence after infertility and in vitro fertilisation. Lancet. 1995;346(8981):995–1000. doi:10.1016/S0140-6736(95)91687-37475593
   PubMed Web of Science ®Google Scholar
• Franceschi S, Vecchia CL, Negri E, et al. Infertility: fertility drugs and risk of epithelial ovarian cancer in Italy. Hum Reprod. 1994;9(9):1673–1675.7836516
   PubMed Web of Science ®Google Scholar
• Jensen A, Sharif H, Frederiksen K, Kjær SK. Use of fertility drugs and risk of ovarian cancer: danish population based cohort study. BMJ. 2009;338:b249. doi:10.1136/bmj.b90219196744
   PubMed Web of Science ®Google Scholar
• Kazerouni N, Greene MH, Lacey JV Jr., Mink PJ, Schairer C. Family history of breast cancer as a risk factor for ovarian cancer in a prospective study. Cancer. 2006;107(5):1075–1083. doi:10.1002/cncr.2208216881078
   PubMed Web of Science ®Google Scholar
• Walsh T, Casadei S, Lee MK, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A. 2011;108(44):18032–18037. doi:10.1073/pnas.111505210822006311
   PubMed Web of Science ®Google Scholar
• Toss A, Tomasello C, Razzaboni E, et al. Hereditary ovarian cancer: not only BRCA 1 and 2 genes. Biomed Res Int. 2015;2015:11.
   Web of Science ®Google Scholar
• Kotsopoulos J, Gronwald J, Karlan B, et al. Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation. Gynecol Oncol. 2018;150(1):85–91. doi:10.1016/j.ygyno.2018.05.01129793803
   PubMed Web of Science ®Google Scholar
• Metcalfe KA, Lynch HT, Ghadirian P, et al. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Gynecol Oncol. 2005;96(1):222–226. doi:10.1016/j.ygyno.2004.09.03915589605
   PubMed Web of Science ®Google Scholar
• Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2002;346(21):1609–1615. doi:10.1056/NEJMoa02011912023992
   PubMed Web of Science ®Google Scholar
• Falconer H, Yin L, Gronberg H, Altman D. Ovarian cancer risk after salpingectomy: a nationwide population-based study. J Natl Cancer Inst. 2015;107:2. doi:10.1093/jnci/dju410
   Google Scholar
• Iordache PD, Mates D, Gunnarsson B, et al. Identification of Lynch syndrome risk variants in the Romanian population. J Cell Mol Med. 2018;22(12):6068–6076. doi:10.1111/jcmm.1388130324682
   PubMed Web of Science ®Google Scholar
• Nakamura K, Banno K, Yanokura M, et al. Features of ovarian cancer in Lynch syndrome. Mol Clin Oncol. 2014;2(6):909–916. doi:10.3892/mco.2014.39725279173
   PubMedGoogle Scholar
• Lu KH, Daniels M. Endometrial and ovarian cancer in women with Lynch syndrome: update in screening and prevention. Fam Cancer. 2013;12(2):273–277. doi:10.1007/s10689-013-9664-523765559
   PubMed Web of Science ®Google Scholar
• Helder-Woolderink J, Blok E, Vasen H, Hollema H, Mourits M, De Bock G. Ovarian cancer in Lynch syndrome; a systematic review. Eur J Cancer. 2016;55:65–73. doi:10.1016/j.ejca.2015.12.00526773421
   PubMed Web of Science ®Google Scholar
• Goodman MT, Wu AH, Tung KH, et al. Association of dairy products, lactose, and calcium with the risk of ovarian cancer. Am J Epidemiol. 2002;156(2):148–157.12117706
   PubMed Web of Science ®Google Scholar
• Pan SY, Ugnat A-M, Mao Y, Sw W, Johnson KC; Group CCRER. A case-control study of diet and the risk of ovarian cancer. Cancer Epidemiol Prev Biomarkers. 2004;13(9):1521–1527.
   PubMed Web of Science ®Google Scholar
• McCann SE, Freudenheim JL, Marshall JR, Graham S. Risk of human ovarian cancer is related to dietary intake of selected nutrients, phytochemicals and food groups. J Nutr. 2003;133(6):1937–1942. doi:10.1093/jn/133.6.193712771342
   PubMed Web of Science ®Google Scholar
• McCann SE, Moysich KB, Mettlin C. Intakes of selected nutrients and food groups and risk of ovarian cancer. Nutr Cancer. 2001;39(1):19–28. doi:10.1207/S15327914nc391_311588898
   PubMed Web of Science ®Google Scholar
• Ong J-S, Cuellar-Partida G, Lu Y, et al. Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. Int J Epidemiol. 2016;45(5):1619–1630. doi:10.1093/ije/dyw20727594614
   PubMed Web of Science ®Google Scholar
• Bandera EV, Lee VS, Qin B, Rodriguez-Rodriguez L, Powell CB, Kushi LH. Impact of body mass index on ovarian cancer survival varies by stage. Br J Cancer. 2017;117(2):282–289. doi:10.1038/bjc.2017.16228588323
   PubMed Web of Science ®Google Scholar
• Delort L, Kwiatkowski F, Chalabi N, Satih S, Bignon YJ, Bernard-Gallon DJ. Central adiposity as a major risk factor of ovarian cancer. Anticancer Res. 2009;29(12):5229–5234.20044641
   PubMed Web of Science ®Google Scholar
• Rodriguez C, Calle EE, Fakhrabadi-Shokoohi D, Jacobs EJ, Thun MJ. Body mass index, height, and the risk of ovarian cancer mortality in a prospective cohort of postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2002;11(9):822–828.12223425
   PubMed Web of Science ®Google Scholar
• Anderson JP, Ross JA, Folsom AR. Anthropometric variables, physical activity, and incidence of ovarian cancer: the Iowa Women’s Health Study. Cancer. 2004;100(7):1515–1521. doi:10.1002/cncr.2014615042687
   PubMed Web of Science ®Google Scholar
• Kotsopoulos J, Moody JR, Fan I, et al. Height, weight, BMI and ovarian cancer survival. Gynecol Oncol. 2012;127(1):83–87. doi:10.1016/j.ygyno.2012.05.03822713293
   PubMed Web of Science ®Google Scholar
• Beehler GP, Sekhon M, Baker JA, et al. Risk of ovarian cancer associated with BMI varies by menopausal status. J Nutr. 2006;136(11):2881–2886. doi:10.1093/jn/136.11.288117056817
   PubMed Web of Science ®Google Scholar
• Leitzmann MF, Koebnick C, Danforth KN, et al. Body mass index and risk of ovarian cancer. Cancer. 2009;115(4):812–822. doi:10.1002/cncr.2408619127552
   PubMed Web of Science ®Google Scholar
• Cottreau CM, Ness RB, Kriska AM. Physical activity and reduced risk of ovarian cancer. Obstet Gynecol. 2000;96(4):609–614.11004368
   PubMed Web of Science ®Google Scholar
• Moorman PG, Jones LW, Akushevich L, Schildkraut JM. Recreational physical activity and ovarian cancer risk and survival. Ann Epidemiol. 2011;21(3):178–187. doi:10.1016/j.annepidem.2010.10.01421296269
   PubMed Web of Science ®Google Scholar
• Huang T, Eliassen AH, Hankinson SE, et al. A prospective study of leisure‐time physical activity and risk of incident epithelial ovarian cancer: impact by menopausal status. Int J Cancer. 2016;138(4):843–852. doi:10.1002/ijc.2983426335147
   PubMed Web of Science ®Google Scholar
• Webb PM, Purdie DM, Bain CJ, Green AC. Alcohol, wine, and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2004;13(4):592–599.15066924
   PubMed Web of Science ®Google Scholar
• Chang ET, Canchola AJ, Lee VS, et al. Wine and other alcohol consumption and risk of ovarian cancer in the California Teachers Study cohort. Cancer Causes Control. 2007;18(1):91–103. doi:10.1007/s10552-006-0083-x17186425
   PubMed Web of Science ®Google Scholar
• Kuper H, Titus-Ernstoff L, Harlow BL, Cramer DW. Population based study of coffee, alcohol and tobacco use and risk of ovarian cancer. Int J Cancer. 2000;88(2):313–318.11004686
   PubMed Web of Science ®Google Scholar
• Tworoger SS, Gertig DM, Gates MA, Hecht JL, Hankinson SE. Caffeine, alcohol, smoking, and the risk of incident epithelial ovarian cancer. Cancer. 2008;112(5):1169–1177. doi:10.1002/cncr.2327518213613
   PubMed Web of Science ®Google Scholar
• Riman T, Dickman PW, Nilsson S, Nordlinder H, Magnusson CM, Persson IR. Some life-style factors and the risk of invasive epithelial ovarian cancer in Swedish women. Eur J Epidemiol. 2004;19(11):1011–1019.15648594
   PubMed Web of Science ®Google Scholar
• Goodman MT, Tung K-H. Alcohol consumption and the risk of borderline and invasive ovarian cancer. Obstet Gynecol. 2003;101(6):1221–1228.12798528
   PubMed Web of Science ®Google Scholar
• Schouten LJ, Zeegers MP, Goldbohm RA, van den Brandt PA. Alcohol and ovarian cancer risk: results from the Netherlands Cohort Study. Cancer Causes Control. 2004;15(2):201–209. doi:10.1023/B:CACO.0000019512.71560.2b15017133
   PubMed Web of Science ®Google Scholar
• Goodman MT, Tung KH. Active and passive tobacco smoking and the risk of borderline and invasive ovarian cancer (United States). Cancer Causes Control. 2003;14(6):569–577. doi:10.1023/A:102482830987412948288
   PubMed Web of Science ®Google Scholar
• Jordan SJ, Green AC, Whiteman DC, Webb PM. Risk factors for benign, borderline and invasive mucinous ovarian tumors: epidemiological evidence of a neoplastic continuum? Gynecol Oncol. 2007;107(2):223–230. doi:10.1016/j.ygyno.2007.06.00617662378
   PubMed Web of Science ®Google Scholar
• Gram IT, Braaten T, Adami HO, Lund E, Weiderpass E. Cigarette smoking and risk of borderline and invasive epithelial ovarian cancer. Int J Cancer. 2008;122(3):647–652. doi:10.1002/ijc.2310817918152
   PubMed Web of Science ®Google Scholar
• Marchbanks PA, Wilson H, Bastos E, Cramer DW, Schildkraut JM, Peterson HB. Cigarette smoking and epithelial ovarian cancer by histologic type. Obstet Gynecol. 2000;95(2):255–260.10674590
   PubMed Web of Science ®Google Scholar
• Pan SY, Ugnat AM, Mao Y, Wen SW, Johnson KC. Association of cigarette smoking with the risk of ovarian cancer. Int J Cancer. 2004;111(1):124–130. doi:10.1002/ijc.2024215185353
   PubMed Web of Science ®Google Scholar
• Modugno F, Ness RB, Cottreau CM. Cigarette smoking and the risk of mucinous and nonmucinous epithelial ovarian cancer. Epidemiology. 2002;13(4):467–471.12094103
   PubMed Web of Science ®Google Scholar
• Gram IT, Lukanova A, Brill I, et al. Cigarette smoking and risk of histological subtypes of epithelial ovarian cancer in the EPIC cohort study. Int J Cancer. 2012;130(9):2204–2210. doi:10.1002/ijc.2623521678398
   PubMed Web of Science ®Google Scholar
• FRANKS AL LEE, Kendrick NC, Rubin JS, et al. Cigarette smoking and the risk of epithelial ovarian cancer. Am J Epidemiol. 1987;126(1):112–117.3591776
   PubMed Web of Science ®Google Scholar
• Su D, Pasalich M, Lee AH, Binns CW. Ovarian cancer risk is reduced by prolonged lactation: a case-control study in southern China. Am J Clin Nutr. 2013;97(2):354–359. doi:10.3945/ajcn.112.04471923283498
   PubMed Web of Science ®Google Scholar
• Jordan SJ, Siskind V, Green AC, Whiteman DC, Webb PM. Breastfeeding and risk of epithelial ovarian cancer. Cancer Causes Control. 2010;21(1):109–116. doi:10.1007/s10552-009-9440-x19779839
   PubMed Web of Science ®Google Scholar
• Booth CM, Li G, Zhang-Salomons J, Mackillop WJ. The impact of socioeconomic status on stage of cancer at diagnosis and survival: a population-based study in Ontario, Canada. Cancer. 2010;116(17):4160–4167. doi:10.1002/cncr.2542720681012
   PubMed Web of Science ®Google Scholar
• Morris CR, Sands MT, Smith LH. Ovarian cancer: predictors of early-stage diagnosis. Cancer Causes Control. 2010;21(8):1203–1211. doi:10.1007/s10552-010-9547-020364367
   PubMed Web of Science ®Google Scholar
• Praestegaard C, Kjaer SK, Nielsen TS, et al. The association between socioeconomic status and tumour stage at diagnosis of ovarian cancer: A pooled analysis of 18 case-control studies. Cancer Epidemiol. 2016;41:71–79. doi:10.1016/j.canep.2016.01.01226851750
   PubMed Web of Science ®Google Scholar
• Alberg AJ, Moorman PG, Crankshaw S, et al. Socioeconomic status in relation to the risk of Ovarian cancer in African-American Women: a population-based case-control study. Am J Epidemiol. 2016;184(4):274–283. doi:10.1093/aje/kwv45027492896
   PubMed Web of Science ®Google Scholar
• Brewster DH, Thomson CS, Hole DJ, Black RJ, Stroner PL, Gillis CR. Relation between socioeconomic status and tumour stage in patients with breast, colorectal, ovarian, and lung cancer: results from four national, population based studies. BMJ. 2001;322(7290):830–831.11290637
   PubMed Web of Science ®Google Scholar